These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
587 related articles for article (PubMed ID: 18227491)
41. Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia. Pan C; Yoo HJ; Ho LT J Obes; 2011; 2011():957268. PubMed ID: 21253513 [TBL] [Abstract][Full Text] [Related]
42. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. Deedwania P Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660 [TBL] [Abstract][Full Text] [Related]
43. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Muls E; Kolanowski J; Scheen A; Van Gaal L; Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595 [TBL] [Abstract][Full Text] [Related]
44. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Tonstad S Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916 [TBL] [Abstract][Full Text] [Related]
45. Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Van Gaal L Clin Cornerstone; 2007; 8 Suppl 6():S24-9. PubMed ID: 17948364 [TBL] [Abstract][Full Text] [Related]
46. The endocannabinoid system as a novel approach for managing obesity. Lillo JL J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530 [TBL] [Abstract][Full Text] [Related]
47. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261 [TBL] [Abstract][Full Text] [Related]
48. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Gelfand EV; Cannon CP J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306 [TBL] [Abstract][Full Text] [Related]
49. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL Clin Endocrinol (Oxf); 2008 Dec; 69(6):931-5. PubMed ID: 18410553 [TBL] [Abstract][Full Text] [Related]
50. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Aronne LJ; Isoldi KK Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742 [TBL] [Abstract][Full Text] [Related]
51. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Aronne LJ; Finer N; Hollander PA; England RD; Klioze SS; Chew RD; Fountaine RJ; Powell CM; Obourn JD Obesity (Silver Spring); 2011 Jul; 19(7):1404-14. PubMed ID: 21293451 [TBL] [Abstract][Full Text] [Related]
53. [Prevention of cardiovascular disease by blocking the endocannabinoid system]. Bramlage P; Schindler C; Thoenes M; Bramlage CP; Böcking W; Kirch W Herz; 2007 Oct; 32(7):560-7. PubMed ID: 17972029 [TBL] [Abstract][Full Text] [Related]
54. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Kintscher U Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715 [No Abstract] [Full Text] [Related]